Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

Detalles Bibliográficos
Autores principales: Schöffski, P, Garfield, D H, Hercbergs, A, Wolter, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856006/
https://www.ncbi.nlm.nih.gov/pubmed/20354526
http://dx.doi.org/10.1038/sj.bjc.6605628
_version_ 1782180224599851008
author Schöffski, P
Garfield, D H
Hercbergs, A
Wolter, P
author_facet Schöffski, P
Garfield, D H
Hercbergs, A
Wolter, P
author_sort Schöffski, P
collection PubMed
description
format Text
id pubmed-2856006
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28560062011-04-13 Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors Schöffski, P Garfield, D H Hercbergs, A Wolter, P Br J Cancer Letter to the Editor Nature Publishing Group 2010-04-13 2010-03-30 /pmc/articles/PMC2856006/ /pubmed/20354526 http://dx.doi.org/10.1038/sj.bjc.6605628 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
Schöffski, P
Garfield, D H
Hercbergs, A
Wolter, P
Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
title Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
title_full Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
title_fullStr Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
title_full_unstemmed Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
title_short Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
title_sort ongoing under-reporting of clinically relevant safety data in phase ii studies of tyrosine kinase inhibitors
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856006/
https://www.ncbi.nlm.nih.gov/pubmed/20354526
http://dx.doi.org/10.1038/sj.bjc.6605628
work_keys_str_mv AT schoffskip ongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors
AT garfielddh ongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors
AT hercbergsa ongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors
AT wolterp ongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors

Ejemplares similares